Condition category
Oral Health
Date applied
27/04/2018
Date assigned
11/05/2018
Last edited
10/05/2018
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Periodontal (gum) disease is common worldwide and is expected to increase due to increased life expectancy. Risk factors identified are mainly poor oral hygiene, poor diet, tobacco use, diabetes and other conditions. It can lead to tooth loss which has many implications such as negative impacts on nutrition and quality of life. The main approach to help prevent periodontal disease is effective daily oral hygiene. Numerous products have been designed to enhance plaque removal and inhibit plaque, including electric toothbrushes, chemotherapeutic pastes and rinses and interdental cleaning aids. The aim of this study is to assess the long-term safety and efficacy of a combination oral hygiene regimen on gingivitis (gum inflammation) among individuals with periodontitis over a period of 2 years.

Who can participate?
Generally healthy volunteers aged 18 and over with periodontitis

What does the study involve?
Participants are randomly allocated to either the regimen group (including antimicrobial paste, rinse, floss and an electric toothbrush) or a control group (standard anti-cavity toothpaste and a regular manual toothbrush). Participants are requested to use their assigned products twice daily at home for the duration of the study (2 years). At the start of the study and months 6, 12, 18 and 24 participants receive oral exams, and gingival inflammation, bleeding and periodontal measurements are assessed. Both groups receive supragingival dental prophylaxis (cleaning above the gum line) every 6 months.

What are the possible benefits and risks of participating?
The study is designed to assess if the participants in the regimen group experience an improvement in oral health. However, there is no general direct immediate benefit to the participants from taking part in this study. Nevertheless, their participation may help in the development of products that aim to improve periodontal health. There are no notable risks involved with participating.

Where is the study run from?
Hadassah - Hebrew University Medical Center (Israel)

When is the study starting and how long is it expected to run for?
February 2014 to February 2016

Who is funding the study?
Procter and Gamble Company (USA)

Who is the main contact?
Prof. Dr Avraham Zini

Trial website

Contact information

Type

Scientific

Primary contact

Prof Avraham Zini

ORCID ID

Contact details

Department of Community Dentistry
Faculty of Dental Medicine
Hadassah - Hebrew University Medical Center
Jerusalem
91120
Israel

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

Clinical Protocol 2013078

Study information

Scientific title

Long-term use of combination oral hygiene on gingival and periodontal health: a pilot study

Acronym

Study hypothesis

The aim of this study is to assess the long-term safety and efficacy of a combination oral hygiene regimen on gingivitis among individuals with concomitant periodontitis over a period of 2 years.

Ethics approval

Hadassah Medical Organization Helsinki Committee, 24/12/2013, IRB Approval #: 0482-13-HMO

Study design

Single-center randomized controlled examiner-blind two-treatment parallel study

Primary study design

Interventional

Secondary study design

Randomised parallel trial

Trial setting

Other

Trial type

Prevention

Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet

Condition

Oral concomitant periodontitis

Intervention

Participants are stratified based on Screening mean Probing Pocket Depth, mean Gingival Bleeding Index, mean age, gender and tobacco use. Within strata, participants are randomly assigned equally to either the regimen group (antimicrobial paste, rinse, floss and an electrical toothbrush) or the control group (standard anti-cavity toothpaste and a regular manual toothbrush).

Participants of the regimen group are instructed to brush their teeth with the assigned electrical toothbrush and dentifrice for two minutes twice a day (morning and evening) following the manufacturer’s usage instructions and to floss the whole mouth once daily for the duration of the study. Participants rinse with water after brushing to remove remaining toothpaste and then rinse with 20ml of the mouth rinse for 30 seconds. Subjects used only the treatment products in place of normal oral hygiene products for the duration of the study.

Participants of the control group are instructed to brush their teeth with the assigned products twice daily (morning and evening) in their customary manner. Subjects are instructed to rinse with water after brushing. Participants use only the treatment products in place of normal oral hygiene products for the duration of the study (they are allowed to continue using floss but they are instructed not to add/change any other oral hygiene products).

Participants are requested to use their assigned products at home for the duration of the study (2 years).

Intervention type

Other

Phase

Drug names

Primary outcome measures

Measured at baseline, month 6, 12, 18 and 24:
1. Gingival inflammation, measured by Modified Gingival Index
2. Bleeding, measured by Gingival Bleeding Index
3. Periodontal measurements (Gingival Recession and Probing Pocket Depth)

Secondary outcome measures

No secondary outcome measures

Overall trial start date

23/02/2014

Overall trial end date

11/02/2016

Reason abandoned

Eligibility

Participant inclusion criteria

1. Give written informed consent and receive a copy of their consent
2. Be between the ages of 18 and 65
3. Be in good general health as determined by the Investigator/designee based on a review of the medical history/update for participation in the study
4. Possess a minimum of 16 natural teeth (excluding third molars) with facial and lingual scorable surfaces
5. Have at least 20 bleeding sites (sum of sites with a score of 1 or 2 on the GBI index)
6. Have at least: 3 eligible healthy sites (PPD <3 mm, no bleeding), 3 eligible gingivitis sites (PPD < 3 mm, bleeding), and 3 eligible periodontal sites (PPD 3-6 mm, bleeding)
7. Agree to delay any elective dentistry until study completion, including additional dental prophylaxes outside the study protocol
8. Agree to refrain from using any non-study oral hygiene products for the study duration (subject will be allowed to continue using floss but they will be instructed not to add/change any other oral hygiene products, including whitening products etc)
9. Agree not to participate in any other oral care clinical study for the duration of this study
10. Agree to return for their scheduled visits and follow study procedures

Participant type

Healthy volunteer

Age group

Adult

Gender

Both

Target number of participants

110

Participant exclusion criteria

1. Severe periodontal disease, as characterized by purulent exudate, generalized mobility, and/or severe recession
2. Active treatment for periodontitis
3. Having a medical condition requiring antibiotic pre-medication prior to dental procedures
4. Fixed facial or lingual orthodontic appliances or removable partial dentures
5. Antibiotic or chlorhexidine use or anti-inflammatory medications within two weeks prior to Screening visit
6. Self-report nursing, pregnancy, or intent to become pregnant during the study
7. Dental prophylaxis within two months prior to the Screening visit
8. Any diseases or conditions that could be expected to interfere with the subject safely completing the study

Recruitment start date

16/02/2014

Recruitment end date

27/02/2014

Locations

Countries of recruitment

Israel

Trial participating centre

Kibbutz Na'an, Israel
76829
Israel

Sponsor information

Organisation

Procter & Gamble

Sponsor details

8700 Mason-Montgomery Road
Mason
45040
United States of America

Sponsor type

Industry

Website

Funders

Funder type

Industry

Funder name

Procter and Gamble

Alternative name(s)

Procter & Gamble, PandG, P&G

Funding Body Type

private sector organisation

Funding Body Subtype

corporate

Location

United States of America

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer reviewed journal

IPD sharing statement
The datasets generated during and/or analysed during the current study are not expected to be made available because if the raw data is available but not analyzed appropriately by qualified experts in the area, it may lead to misinterpretation of the results. Study protocol, statistical analysis plan, and other additional documents are not intended to become available online.

Intention to publish date

31/12/2019

Participant level data

Not expected to be available

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes